Pasar al contenido principal

CARACTERIZACION MOLECULAR DE PATRONES GENOMICOS Y FENOTIPICOS RELACIONADOS CON RESISTENCIA A LA TERAPIA NEOADYUVANTE EN CARCINOMAS DE MAMA TRIPLES NEGATIVOS Y HER2+

PI19/01371

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer

  • Pons, Laura|||0000-0003-0784-4110
  • Hernández, Laura
  • Urbizu, Aintzane|||0000-0001-8458-1209
  • Osorio, Paula
  • Rodríguez-Martínez, Paula|||0000-0002-9001-2501
  • Castellà Fernández, Eva
  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Sanz, Carolina|||0009-0001-9228-755X
  • Arnaldo, Laura|||0000-0003-1654-0573
  • Felip, Eudald|||0000-0002-3812-1313
  • Quiroga García, Vanesa
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Margelí, Mireia|||0000-0003-3594-4530
  • Fernández, Pedro Luis|||0000-0002-8618-4597
HER2+ and triple negative breast cancers are widely known for their aggressiveness, frequent resistance to treatment and poor prognosis. Neoadjuvant management has provided promising results for both subtypes, but there is still a subset of patients with no or low response. Consequently, a non-negligible number of patients is receiving a treatment regimen that might not be adequate. Identification of these patients is essential to avoid overtreatment and provide more effective treatment options. Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correlation of clinicopathological factors with pCR was studied in 150 patients (HER2 = 81; TN = 69) and pre- and post-NAT differences in tumour biomarkers were compared. Low estrogen receptor (ER) expression, high tumour-infiltrating lymphocytes (TILs) and low cT-stage were associated with pCR in HER2+ tumours (p = 0.022; p = 0.032 and p = 0.005, respectively). Furthermore, ER expression was also associated with residual cancer burden (RCB; p = 0.046) in the HER2+ subtype. Similarly, pre-NAT, low progesterone receptor expression (PR; 1-10%) was associated with higher RCB (p < 0.001) in TN tumours. Only clinical and pathological T-stage (cpT-stage) had prognostic capacity in HER2+ tumours, whereas pre-NAT cpT-stage and post-NAT TILs had this capacity for the prognosis of TN tumours. We conclude that ER and PR expression may help predict response to NAT in HER2 and TN BC and should be taken into account in residual tumours. Also, changes observed in the phenotype after NAT suggest the need to reevaluate biomarkers in surviving residual tumour cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer

  • Pons, Laura|||0000-0003-0784-4110
  • Hernández-León, Laura
  • Altaleb, Ahmad
  • Ussene, Esperança
  • Iglesias, Roman
  • Castillo, Ana
  • Rodríguez-Martínez, Paula|||0000-0002-9001-2501
  • Castellà Fernández, Eva
  • Quiroga García, Vanesa
  • Felip, Eudald|||0000-0002-3812-1313
  • Cirauqui, Beatriz|||0000-0002-0136-8056
  • Margelí, Mireia|||0000-0003-3594-4530
  • Fernández, Pedro Luis|||0000-0002-8618-4597
Digital counting methods were developed to decrease the high intra- and inter-observer variability of immunohistochemical markers such as Ki67, with most presenting a good correlation coefficient (CC). Since Ki67 is one of the major contributors to Oncotype DX, it is conceivable that Ki67 expression and the recurrence score (RS) obtained by the multigene panel are positively correlated. We decided first to test to what extent conventional and digital Ki67 quantification methods correlate in daily practice and, second, to determine which of these methods correlates better with the prognostic capacity of the Oncotype DX test. Both Ki67 evaluations were performed in 89 core biopsies with a diagnosis of estrogen receptor (ER) positive HER2-negative breast cancer (BC). Cases were, thus, classified twice for surrogate subtype: first by conventional analysis and then by digital evaluation. The Oncotype RS was obtained in 55 cases that were subsequently correlated to Ki67 evaluation by both methods. Conventional and digital Ki67 evaluation showed good concordance and correlation (CC = 0.81 (95% CI 0.73-0.89)). The correlation of Oncotype DX risk groups and surrogate derived subtypes was slightly higher for the digital technique (r = 0.46, p < 0.01) compared to the conventional method (r = 0.39, p < 0.01), even though both were statistically significant. In conclusion, we show that digital evaluation could be an alternative to conventional counting, and also has advantages for predicting the risk established by the Oncotype DX test in ER-positive BC. This study also supports the importance of an accurate Ki67 analysis which can influence the decision to submit ER-positive HER2-negative BC to prognostic molecular platforms.